Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PEN 
Penumbra Inc (PEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: PEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $303.33
1 Year Target Price $303.33
| 12 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.59% | Avg. Invested days 47 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.26B USD | Price to earnings Ratio 69.38 | 1Y Target Price 303.33 |
Price to earnings Ratio 69.38 | 1Y Target Price 303.33 | ||
Volume (30-day avg) 18 | Beta 0.45 | 52 Weeks Range 185.13 - 310.00 | Updated Date 09/17/2025 |
52 Weeks Range 185.13 - 310.00 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.54% | Operating Margin (TTM) 12.03% |
Management Effectiveness
Return on Assets (TTM) 6.2% | Return on Equity (TTM) 12.03% |
Valuation
Trailing PE 69.38 | Forward PE 52.63 | Enterprise Value 10051176961 | Price to Sales(TTM) 8.01 |
Enterprise Value 10051176961 | Price to Sales(TTM) 8.01 | ||
Enterprise Value to Revenue 7.85 | Enterprise Value to EBITDA 51.9 | Shares Outstanding 38999100 | Shares Floating 37804976 |
Shares Outstanding 38999100 | Shares Floating 37804976 | ||
Percent Insiders 3.66 | Percent Institutions 93.38 |
Upturn AI SWOT
Penumbra Inc
Company Overview
History and Background
Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California. The company focuses on developing and marketing innovative medical devices for neurovascular and vascular diseases. It has grown from a small startup to a publicly traded company with a global presence.
Core Business Areas
- Vascular: Develops and markets products for peripheral vascular diseases, including thrombectomy devices and access systems. Products include Indigo System, and Ruby System.
- Neuro: Develops and markets products for neurovascular diseases, including stroke and aneurysm treatment. Products include RED reperfusion catheters, and POD coil system.
Leadership and Structure
Adam Elsesser serves as the Chairman, President, and Chief Executive Officer. The company has a standard corporate structure with departments for R&D, marketing, sales, operations, and finance.
Top Products and Market Share
Key Offerings
- Indigo System: A thromboaspiration system used to remove thrombi in the peripheral vasculature. Penumbra estimated market share of around 35% in the large bore aspiration thrombectomy market in 2023. Competitors include Boston Scientific, Medtronic, and Stryker.
- RED Reperfusion Catheters: Designed for mechanical thrombectomy in acute ischemic stroke. Competitors include Medtronic, Stryker and Johnson & Johnson.
- Lightning Flash: An intelligent thromboaspiration system designed to deliver automated, clot-specific vacuum in the venous system and reduce blood loss. The main competitor for this product is Inari Medical.
Market Dynamics
Industry Overview
The neurovascular and vascular medical device industries are characterized by innovation, competition, and increasing demand due to aging populations and rising prevalence of related diseases.
Positioning
Penumbra is positioned as an innovator in the neurovascular and vascular device space, known for its aspiration thrombectomy technology. The company competes with larger, more established players.
Total Addressable Market (TAM)
The TAM for thrombectomy devices is estimated to be in the billions of dollars. Penumbra is positioned to capture a significant portion of this market through innovation and market penetration.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Strong focus on R&D
- Established sales network
- Proprietary technology
- Increasing revenue growth
Weaknesses
- Product recalls due to safety concerns
- Reliance on a few key products
- Smaller size compared to competitors
- Dependence on regulatory approvals
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing technologies
- Acquiring complementary technologies
- Increasing adoption of minimally invasive procedures
Threats
- Intense competition from larger players
- Product liability lawsuits
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- MDT
- BSX
- STRY
Competitive Landscape
Penumbra faces stiff competition from larger, more established players. Penumbra's competitive advantages include its innovative product portfolio and strong focus on R&D. However, its smaller size and dependence on regulatory approvals are disadvantages.
Major Acquisitions
MVI Health
- Year: 2021
- Acquisition Price (USD millions): 44
- Strategic Rationale: Expanded Penumbra's portfolio of virtual reality-based healthcare solutions.
Growth Trajectory and Initiatives
Historical Growth: Penumbra has demonstrated strong revenue growth in recent years, driven by the adoption of its innovative products.
Future Projections: Analyst estimates project continued revenue growth for Penumbra, driven by new product launches and market expansion. Analyst projects a 12-15% growth.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new products, and pursuing strategic acquisitions.
Summary
Penumbra demonstrates innovation in the neurovascular and vascular space, with strong revenue growth driven by novel products. Potential product liability lawsuits present a risk, along with reliance on regulatory approvals. Competitors outsize Penumbra, however Penumbra is addressing a sizable market. The expansion in sales will boost future growth and help capture market share from competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Analyst Reports
- Industry Publications
- Penumbra Investor Relations
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data can change and inaccuracies can exist. Invest with caution and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Penumbra Inc
Exchange NYSE | Headquaters Alameda, CA, United States | ||
IPO Launch date 2015-09-18 | Co-Founder, Chairman & CEO Mr. Adam Elsesser J.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 4500 | Website https://www.penumbrainc.com |
Full time employees 4500 | Website https://www.penumbrainc.com | ||
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.